证券代码：002821 证券简称：凯莱英 公告编号：2025-035 凯莱英医药集团（天津）股份有限公司 关于 A 股限制性股票首次授予登记完成的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或重大遗漏。 重要内容提示 | 姓名 | 职务 | 获授的限制性股 | 占首次授予限制性 | 占目前公司 A 股 | | --- | --- | --- | --- | --- | | | | 票数量（万股） | 股票总数的比例 | 股本总额的比例 | | 张达 | 执行董事，首 席运营官，首 席财务官 | 6.50 | 1.5211% | 0.0195% | | 陈朝勇 | 执行副总裁 | 5.00 | 1.1701% | 0.0150% | | 姜英伟 | 执行副总裁 | 5.00 | 1.1701% | 0.0150% | | 周炎 | 高级副总裁 | 4.00 | 0.9360% | 0.0120% | | 徐向科 | 高级副总裁兼 董事会秘书 | 4.00 | 0.9360% | 0.0120% | | 张婷 | 非执行董事 | 3.00 | 0.7020% | 0.00 ...

截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年6月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 ...

Group 1 - Hong Kong pharmaceutical stocks are rising, with Kelaiying (002821) increasing by over 7% [1] - Other companies such as Kanglong Chemical (300759), WuXi Biologics, WuXi AppTec (603259), and Zhaoyan New Drug (603127) are also experiencing gains [1] Group 2 - A-share accounts can now buy Hong Kong stocks with T+0 trading without the need for Hong Kong Stock Connect [2]

证券代码：002821 证券简称：凯莱英 公告编号：2025-034 特别提示： 1、凯莱英医药集团（天津）股份有限公司（以下简称"公司"）本次回购 注销 A 股限制性股票涉及 1 名 2020 年限制性股票激励计划预留授予离职激励 对象孙学惠持有的 1,680 股，占公司回购注销前 A+H 总股本 360,595,400 股的 0.0005%。本次回购价格为 102.46 元/股，回购款共计人民币 172,132.80 元。 2、截至目前，公司已在中国证券登记结算有限责任公司深圳分公司办理完 成上述 A 股限制性股票回购注销手续。 2、2020 年 6 月 24 日至 2020 年 7 月 3 日，公司对首次授予激励对象的姓名 和职务在公司官网进行了公示，截至公示期满，公司监事会未接到任何人对公司 本次拟激励对象提出异议。2020 年 7 月 4 日，公司披露了《监事会关于 2020 年 凯莱英医药集团（天津）股份有限公司 关于部分 A 股限制性股票回购注销完成的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 3、本次回购注销完成后，公司 A+H 股份总数 ...

Group 1 - The pharmaceutical sector in Hong Kong is experiencing a strong rally, with notable gains in stocks such as Kailaiying, which rose over 14%, and Sangfor Pharmaceuticals, which increased by 7.6% [1][2] - Sangfor Pharmaceuticals announced a licensing agreement with Pfizer, receiving an upfront payment of $1.25 billion, which significantly boosted investor confidence [1] - The China National Medical Products Administration has accepted a new drug application for cyclosporine eye gel from Zhaoke Ophthalmology, indicating positive regulatory developments in the industry [1] Group 2 - Longcheng Securities expressed optimism about the pharmaceutical sector, citing frequent favorable policies that are expected to lead to a steady recovery in industry sentiment [1] - Morgan Stanley's research report maintains a positive outlook on the Chinese pharmaceutical industry, highlighting supportive policies for innovation and low dependency on U.S. exports, which mitigates risks from geopolitical tensions and uncertainties in U.S. drug pricing [1]

Group 1 - A-shares market showed positive performance with all three major indices rising on May 21, 2023, indicating a favorable market sentiment [1] - A500 Index ETF (159351) recorded a 0.21% increase with a trading volume exceeding 1 billion yuan, leading in trading volume among similar products [1] - The A500 Index ETF closely tracks the CSI A500 Index, which selects 500 stocks representing strong market capitalization across various industries, achieving a balance between large-cap stocks and core industry leaders [1] Group 2 - Recent reduction in loan market quotation rates (LPR) by 10 basis points to 3.0% for 1-year and 3.5% for over 5 years is expected to enhance financial support for the real economy [2] - The decrease in LPR and deposit rates is anticipated to lower overall financing costs, stabilize market expectations, and stimulate credit demand, thereby promoting corporate investment [2] - The adjustment in LPR aligns with the recent cut in the central bank's reverse repo rate, indicating a coherent monetary policy approach [2] Group 3 - The A-share market is shifting towards core assets, with financial and real estate sectors leading in gains, while the technology sector is under pressure [3] - The introduction of new public fund regulations reflects a long-term transformation in China's capital and economic structures, suggesting a potential decline in manufacturing expansion [3] - The return to core asset styles indicates a market correction demand in the short term and signals a potential economic cycle bottoming out in the long term [3]

证券代码：002821 证券简称：凯莱英 公告编号：2025-033 国公司法》、《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的相关规定。 现场会议召开时间：2025年6月11日下午14:00 网络投票时间：2025年6月11日，其中，通过深圳证券交易所交易系统进行 网络投票的时间为2025年6月11日上午9：15-9：25，9：30-11：30，下午13:00- 凯莱英医药集团（天津）股份有限公司 关于召开2024年度股东大会、2025年第二次A股类别股东 大会及2025年第二次H股类别股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）将于2025年6月 类别股东大会及2025年第二次H股类别股东大会。现将本次会议有关事项公告如 下： 一、召开会议的基本情况 年第二次H股类别股东大会 （1）现场投票：股东本人出席现场会议或者通过授权委托书（见附件）委 托他人出席现场会议；公司H股股东可以通过现场或委托投票方式参加本次股东 大会，有关具体方式参见 ...

Core Insights - Gao Yi Asset Management recently conducted research on a listed company, Kailai Ying, revealing positive financial performance in Q1 2025 [1] Financial Performance Summary - Kailai Ying reported a main revenue of 1.541 billion yuan, an increase of 10.1% year-on-year [1] - The net profit attributable to shareholders was 327 million yuan, reflecting a year-on-year growth of 15.83% [1] - The net profit after deducting non-recurring items was 305 million yuan, up by 20.14% year-on-year [1] - The company's debt ratio stood at 11.58% [1] - Investment income amounted to 10.2752 million yuan, while financial expenses were -44.9396 million yuan [1] - The gross profit margin was reported at 42.54% [1] Company Overview - Gao Yi Asset Management is a prominent private equity fund management company in China, known for its strong research capabilities and large management scale [2] - The firm focuses on capital markets and aims to provide top-notch research support and resources to its investment managers [2] - The investment team consists of over 30 members, including experienced managers and award-winning fund managers from leading fund companies [2] - The company is registered in Shanghai and has teams located in Shenzhen, Shanghai, and Beijing [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company achieved a revenue of 1.541 billion yuan in Q1 2025, representing a year-over-year growth of 10.10%, and a net profit attributable to shareholders of 327 million yuan, with a year-over-year increase of 15.83%. The non-recurring net profit was 305 million yuan, reflecting a year-over-year growth of 20.14% [1] - The emerging business segment saw revenue growth exceeding 80% year-over-year, driven by increased market expansion efforts and enhanced competitiveness, particularly in peptide, oligonucleotide, and ADC businesses. The outlook for the emerging business remains positive [1][2] - The gross margin for Q1 2025 was 42.54%, with the emerging business gross margin significantly improving to 33.05%, a year-over-year increase of 15.75%. This improvement is attributed to higher capacity utilization from sustained order deliveries [2] - The company forecasts EPS for 2025-2027 to be 2.90, 3.45, and 4.19 yuan, respectively, with a PE ratio of 23 times based on the closing price on April 23, 2025. The company is expected to maintain strong growth potential, particularly in the emerging business segment [2] Financial Summary - For 2025E, the company expects revenue of 6.629 billion yuan, a year-over-year increase of 14.21%, and a net profit of 1.045 billion yuan, reflecting a growth of 10.16% [7] - The gross margin is projected to be 42.43% in 2025E, with a net margin of 15.72% [8] - The company’s total assets are expected to reach 21.751 billion yuan by 2025E, with total liabilities of 2.771 billion yuan [8]

Investment Rating - The report maintains an "Accumulate" investment rating for the company [3]. Core Insights - The company reported a revenue of 1.541 billion yuan in Q1 2025, representing a year-over-year increase of 10.10%, and a net profit of 327 million yuan, up 15.83% year-over-year [1]. - The net profit margin improved to approximately 21.06% in Q1 2025, an increase of 1.09 percentage points year-over-year and 6.91 percentage points quarter-over-quarter, attributed to cost reduction measures and rapid growth in emerging businesses [6]. - The small molecule CDMO business showed stable progress with revenue approximately at 1.223 billion yuan, maintaining year-over-year stability, while the emerging service business grew over 80% year-over-year, with revenue exceeding 317 million yuan in Q1 2025 [6]. - The company aims for double-digit revenue growth for the full year, supported by strong order trends, particularly from European and American clients, with a projected revenue of 6.617 billion yuan for 2025 [6]. Financial Data and Valuation - The company’s total revenue is projected to decline by 24% in 2023, followed by a 26% decline in 2024, before recovering with a 14% growth in 2025 [2][10]. - The estimated earnings per share (EPS) for 2025 is 2.99 yuan, with a price-to-earnings (PE) ratio of 22.4 [2][10]. - The company’s return on equity (ROE) is projected to be 6% in 2025, with a gradual increase to 8% by 2027 [10]. Shareholder Information - The major shareholder, ASYMCHEM LABORATORIES INCORPORATED, holds a 31.93% stake in the company [3]. Market Performance - The company's stock price is currently at 67.06 yuan, with a total market capitalization of 24.2 billion yuan [3].